Study to Evaluate the Safety, Immunogenicity, and Efficacy of Nanocovax Vaccine Against COVID-19
Clinical trial NCT04922788 · COMPLETED
Trial details
- NCT number
- NCT04922788
- Sponsor
- Nanogen Pharmaceutical Biotechnology Joint Stock Company
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2021-06-07
- Primary completion
- 2022-07-20
- Enrollment
- 13006
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.